Address
131 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
415 231 5660
Website
Sector
Healthcare
Industry
Biotechnology
Employees
103
First IPO Date
February 07, 2019
| Name | Title | Pay | Year Born |
| Arnon Rosenthal | Co-Founder, Chief Executive Officer & Director | 1.01M | 1956 |
| Neil Berkley | CFO & Chief Business Officer | 705,122 | 1974 |
| Giacomo Salvadore | Chief Medical Officer | 752,171 | N/A |
| Hua Long DABT | Senior VP & Head of Research | 0 | N/A |
| Clare Hunt | Chief People & Places Officer | 0 | N/A |
| Katie Hogan | Senior Director of Corporate Communication & Investor Relations | 0 | N/A |
| Kristina Cutter | Chief Development Officer | 0 | N/A |
| Danielle Pasqualone | General Counsel | 0 | N/A |
| Eric Brown | Director of Antibody Discovery & Protein Engineering | 0 | N/A |
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.